Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
The post Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s appeared first on Business News.
You may also like
Leave a Reply